Biobetters Market

Global Market Study on Biobetters: Lower Dosage Frequency to drive market expansion

Biobetters Market Segmented by erythropoietin biobetters, G-CSF biobetters, interferon biobetter, insulin biobetters, monoclonal antibodies biobetters, antihemophilic factors Drugs Class as diabetes, cancer, renal disease, neurodegenerative disease, genetic disorders Indications by subcutaneous and intravenous Route of Administration

Report ID: PMRREP21151

Number of Pages: 242

Format: PPT*, PDF, EXCEL

Industry: Healthcare

Published Date: May-2022

Report Price


Buy Now

Biobetters Market Outlook (2022 - 2029)

Biobetters Market witnessed a CAGR of 7.3% between 2014 and 2021. The global Biobetters Market is expected to witness a steady 8.3% CAGR between 2022 and 2029. In 2022, the global Biobetters Market size was US$ 55,752.3 million, which is projected to reach US$ 99,262.5 million by the year 2029.

Attribute Key Insights

Biobetters Market Size (2022)

US$ 55,752.3 Mn

Projected Market Value (2029)

US$ 99,262.5 Mn

Global Market Growth Rate (2022-2029)

8.6% CAGR

Share in parent market


Sample Report

Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get Report Sample

Biobetters Market Demand Analysis (2014-2021) v/s Market Outlook (2022 – 2029)

Biobetters, also known as biosuperiors, are recombinant protein drugs from an identical class as a present set of biopharmaceuticals is not similar to the source. It is neither a wholly novel medicine nor a generic version of an old drug. It is a biological product designed to increase clinical efficacy while also improving tolerance and lowering dosing/administration frequency. The Biobetters Market is expected to witness a CAGR of 8.6% due to the advantages of Biobetters such as superior therapeutic efficacy, lesser side effects, easier and less expensive production methods, non-patent and market exclusivity, longer product half-life, lower dosage frequency, and the availability of high investment prospects.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What is expected to keep the Hopes High for Biobetters Market?

High Efficacy and Few Side Effects

Biobetters are designed to be enhanced variants of existing biologics in terms of therapeutic benefit, dose frequency, side effects, and so on. Furthermore, they are intended to be more effective than already available biologics. Furthermore, due to the low dosing frequency, patients usually complete their entire treatment cycle. Hence, the Biobetters market is expected to grow significantly going forward.


Simple and Less Expensive Manufacturing Process

The manufacturing procedure of biobetters is identical to that of biologics; however, modern technologies such as pegylation, albumin replacement, and so on are used as well. Several manufacturers are effectively employing these techniques in the production of different biobetters. Biobetters have a lower development cost and take roughly 10 years to develop, whereas biologics demand a greater investment and take approximately 15 years to develop. While biosimilars have a cost of development that is almost half that of biobetters, their therapeutic effectiveness is far superior.

“Increasing Research Activities”

Manufacturers and investors in the biobetters industry are continuously focused on developing better formulations. Biopharmaceuticals are looking for novel techniques to evaluate complicated structures in order to build better biobetters. An array of biophysical and biochemical approaches have arisen in recent years in the evolution of the biobetters industry, offering a significant push to its expansion.

Increased Investment in Developing Therapeutic Agents

Increasing investment in developing therapeutic agents with enhanced effectiveness and safety profiles for cancers and autoimmune illnesses has influenced the biobetters market's growth dynamics. There have been considerable attempts in recent years to reduce the economic impact of chronic illnesses. The increasing investment in developing new drugs is likely to fuel market growth in the near future.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

What restraints is the Biobetters Market subject to?

“High Investments Required for R&D Activities”

Developing novel medicinal drugs necessitates large investments in the research and development process, which limits the market growth. However, since the Covid-19 virus outbreak, there has been a huge rise in R&D spending for developing novel biobetters. Apart from that, rising biosimilar competition is also restricting the market growth.

How has Covid-19 affected the Biobetters Market?

“Increase in the investment for developing novel biobetters”

There has been a significant increase in R&D investment for developing novel biobetters since the Covid-19 virus outbreak. Manufacturers and investors in the biobetter industry are constantly working to improve formulations, and many novel medications are in the pipeline or clinical trials.

Competitive Landscape

The Biobetters market is highly competitive and consists of significant major players, that dominate the market. The market players are focusing on mergers and strategic alliances as the industry is in the growth phase.

Recent Developments:

  • Green Cross Corp, one of the global leaders in biobetters, is currently developing a margetuximab biobetter in partnership with American biotech MacroGenics.

Biobetters Market Industry Report Scope

Attribute Details

Forecast Period


Historical Data Available for


Market Analysis

US$ Mn/Bn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Covered

  • U.S.
  • Canada
  • Germany
  • Italy
  • France
  • U.K.
  • Spain
  • Russia
  • India
  • China
  • Japan
  • UAE
  • Australia

Key Market Segments Covered

By Distribution Channel

Key Companies Profiled

  • F.Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Sanofi SA
  • Porton Biopharma Limited
  • Eli Lily and Company
  • Novo Nordisk A/S
  • Biogen Inc.
  • CSL Behring GmbH
  • Teva Pharmaceutical Industries Ltd.

Customization & Pricing

Available upon Request

Biobetters Market Categorization

Biobetters Market by By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Biobetters Market By Molecule Type

  • G-CSF Biobetters
  • Insulin Biobetters
  • Erythropoietin Biobetters
  • Monoclonal Antibodies Biobetters
  • Others

Biobetters Market by Disease Indication

  • Cancer
  • Diabetes
  • Genetic disease
  • Neurological Disorders
  • Others

Biobetters Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

For report customisation and delivery information contact our sales representative.

Companies Covered in This Report

  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Sanofi SA
  • Porton Biopharma Limited
  • Eli Lily and Company
  • Novo Nordisk A/S
  • Biogen Inc.
  • CSL Behring GmbH
  • Teva Pharmaceutical Industries Ltd.

Frequently Asked Questions

In 2022, the Biobetters Market stands at USD 55,752.3million, and it is expected to reach USD 99,262.5 million by 2029 at a CAGR of 8.6%.

Biobetters Market exhibited a 7.3% CAGR between 2014 and 2021.

High investments and rising biosimilar competition are the key restraints in the Biobetters Market.

High Efficacy and Few Side Effects of Biobetters are the key factors driving the growth of the market.

F.Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, SERVIER, and Porton Biopharma Limited are among the top players in the market.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate